已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Identifying disease-modifying potential in myelofibrosis clinical trials

代理终结点 骨髓纤维化 医学 鲁索利替尼 临床试验 临床终点 重症监护医学 疾病 肿瘤科 内科学 骨髓
作者
David M. Ross,Steven Lane,Claire Harrison
出处
期刊:Blood [American Society of Hematology]
标识
DOI:10.1182/blood.2024024220
摘要

The ultimate goal of bringing most new drugs to the clinic in hematological malignancy is to improve overall survival. However, the use of surrogate endpoints for overall survival is increasingly considered standard practice, since a well validated surrogate endpoint can accelerate the outcome assessment and facilitate better clinical trial design. Established examples include monitoring minimal residual disease in chronic myeloid leukemia and acute leukemia, and metabolic response assessment in lymphoma. However, what happens when a clinical trial endpoint that is not a good surrogate for disease-modifying potential becomes ingrained as an expected outcome, and new agents are expected or required to meet this endpoint to demonstrate "efficacy"? JAK inhibitors for myelofibrosis have a specific impact on reducing symptom burden and splenomegaly, but limited impact on the natural history of the disease. Since the introduction of ruxolitinib more than a decade ago there has been modest incremental success in clinical trials for myelofibrosis, but no major leap forward to alter the natural history of the disease. We argue that the clinical development of novel agents for myelofibrosis will be accelerated by moving away from using endpoints that are specifically tailored to measure the beneficial effects of JAK inhibitors. We propose that specific measures of relevant disease burden, such as reduction in mutation burden as determined by molecular endpoints, should replace established endpoints. Careful re-analysis of existing data and trials in progress is needed to identify the most useful surrogate endpoints for future MF trials and better serve patient interest.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
insomnia417完成签到,获得积分0
1秒前
光亮如彤完成签到,获得积分10
3秒前
4秒前
4秒前
4秒前
白蓝完成签到 ,获得积分10
4秒前
不与仙同完成签到 ,获得积分10
6秒前
9秒前
jjj完成签到 ,获得积分10
9秒前
9秒前
科研通AI2S应助科研通管家采纳,获得10
11秒前
莫言应助科研通管家采纳,获得50
11秒前
11秒前
科研通AI2S应助科研通管家采纳,获得10
11秒前
策策策策策完成签到 ,获得积分0
11秒前
科研通AI2S应助科研通管家采纳,获得10
11秒前
rita_sun1969完成签到,获得积分10
11秒前
科研通AI2S应助科研通管家采纳,获得10
11秒前
科目三应助科研通管家采纳,获得10
11秒前
summer发布了新的文献求助10
11秒前
大个应助科研通管家采纳,获得10
11秒前
JamesPei应助科研通管家采纳,获得30
12秒前
12秒前
打打应助11采纳,获得10
16秒前
打打应助黄小强采纳,获得10
16秒前
Simpson完成签到 ,获得积分10
19秒前
独特的娩完成签到 ,获得积分10
20秒前
张云清完成签到,获得积分10
21秒前
21秒前
che完成签到,获得积分10
22秒前
cccc完成签到,获得积分10
22秒前
sb完成签到,获得积分20
24秒前
葡萄皮完成签到,获得积分10
25秒前
25秒前
Jasper应助小锤采纳,获得10
26秒前
sb发布了新的文献求助10
28秒前
参苓白术炒扁豆完成签到,获得积分10
28秒前
尧尧完成签到 ,获得积分10
29秒前
黄小强发布了新的文献求助10
31秒前
32秒前
高分求助中
中国国际图书贸易总公司40周年纪念文集 大事记1949-1987 2000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
草地生态学 880
Threaded Harmony: A Sustainable Approach to Fashion 799
Basic Modern Theory of Linear Complex Analytic 𝑞-Difference Equations 510
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Livre et militantisme : La Cité éditeur 1958-1967 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3059398
求助须知:如何正确求助?哪些是违规求助? 2715371
关于积分的说明 7444724
捐赠科研通 2360874
什么是DOI,文献DOI怎么找? 1251017
科研通“疑难数据库(出版商)”最低求助积分说明 607671
版权声明 596448